27 C
Vientiane
Tuesday, October 7, 2025
spot_img
Home Blog Page 134

BOE launches sustainable development strategy and joint initiative, mapping out a new blueprint for high-quality and sustainable development

BEIJING, Sept. 23, 2025 /PRNewswire/ — At the just-concluded BOE Global Innovation Partner Conference 2025 (BOE IPC 2025), BOE unveiled its sustainable development strategy, and joined forces with key partners to release the Joint Initiative for Sustainable Development, making it an important component of the Group’s strategy. BOE, a world-leading IoT innovation company, has consistently integrated sustainable development into its organizational DNA. The display giant has not only pursued sustainable development as a key strategy but also embedded the concept in every aspect, ranging from technological innovation and green and low-carbon practices to corporate governance and social impact initiatives. All these serve to ensure stable operations and high-quality and sustainable development.

Over the past year, BOE has doubled down on building its sustainable development system and made active moves in the field of sustainable development. In December 2024, the company established a three-level organizational structure for sustainable development, which comprises the governance, management, and execution levels. This reflects the unprecedented importance that BOE has attached to sustainable development. In April this year, BOE launched the industry’s first sustainability brand “ONE” (Open Next Earth) in an effort to build a win-win ecosystem, marking another milestone in brand building. At BOE IPC 2025, BOE released the Group’s sustainable development strategy, which is based upon six strategic pillars: Open Innovation, Environmental Sustainability, Society, Humanity, Responsible Company, and Genesis Field, spurring the company to move from leadership in technology to leadership in sustainability. Furthermore, together with the China Electronics Chamber of Commerce, the China Video Industry Association, the China Optics and Optoelectronics Manufacturers Association LCB, the Society for Information Display, the China-BRICS Artificial Intelligence Development and Cooperation Center, and the China Software Testing Center, BOE and its ecosystem partners like Hisense, Meta, E Ink, Lenovo, 3M, and DNP launched the Joint Initiative For Sustainable Development:

Co-expansion – Embracing open collaboration to jointly expand the innovation pathways;

Sharing – Taking people-centric approaches to share the benefits of technological empowerment.

Win-Win – Implementing green practices as the foundation for a win-win ecosystem;

Build together – Sticking to long-term, responsible strategies to build a sustainable future.

With a full-fledged sustainable development system, BOE will stick to the path of market-oriented, international, and professional development, further solidify its leadership in the semiconductor display sector, and embed sustainable development in every aspect of corporate operations and management, thus underpinning its global business growth.

Pudu Robotics Launches Self-Cleaning Docking Station for PUDU CC1 Series – Redefining Hands-Free Cleaning

BERLIN, Sept. 23, 2025 /PRNewswire/ — Pudu Robotics, a global leader in service robotics, today announced the launch of the Self-Cleaning Docking Station, the latest addition to the PUDU CC1 Series ecosystem. The new docking station enables the PUDU CC1 series to perform automated, dock-assisted cleaning cycles that keep critical cleaning components in peak condition while substantially reducing routine upkeep.

PUDU Self-Cleaning Docking Station for PUDU CC1 Series – Redefining Hands-Free Cleaning
PUDU Self-Cleaning Docking Station for PUDU CC1 Series – Redefining Hands-Free Cleaning

The Self-Cleaning Docking Station expands Pudu’s portfolio of cleaning solutions which includes the standard Docking Station for automated refilling, drainage, and charging, and the Mobile Water Station for flexible deployment in facilities without direct plumbing access. Together, these innovations give facility operators a complete set of tools for achieving consistent, unattended cleaning.

Key Features of the Self-Cleaning Docking Station

  • Squeegee Deep Cleaning Technology
    With a built-in 100W ultrasonic module and 65℃ / 149°F hot water system, the station thoroughly cleans the CC1’s squeegee, removing dirt and residue to prevent streaks and secondary pollution.
  • Automated Roller Brush Cleaning
    After each cleaning task, CC1 docks for automatic roller brush cleaning. The system removes over 95% of debris, prevents tangling, and helps extend the brush’s service life.
  • Smart Stain Detection & Response
    Paired with the CC1 Pro’s onboard stain detection, the system forms a closed-loop workflow: detect → dock → self-clean → resume operation, preventing contamination spread and maintaining high cleaning standards.
  • 35x Maintenance Efficiency Improvement
    By automating daily cleaning of the squeegee and roller brush, the station reduces routine upkeep from minutes per day to just a simple water tank rinse once per week.
  • Three Configurations in One System
    The modular quick-swap design allows three setups: Standard Docking Station, Self-Cleaning Docking Station, or Pro version. This flexibility ensures compatibility with everything from compact stores to large facilities.
  • Modular Design for Easy Care
    Roller brush cleaner, squeegee, and water tank are all quick-release, enabling fast, tool-free maintenance by a single operator.

In addition to these highlights, the station retains all core features of the original Docking Station—automatic refilling, drainage, detergent dosing, and charging—and is fully compatible with the Mobile Water Station for facilities without water lines.

A New Benchmark for Autonomous Cleaning

“The Self-Cleaning Docking Station makes it easier than ever for businesses to maintain consistent cleaning performance,” said Felix Zhang, Founder and CEO of Pudu Robotics. “By enabling robots to maintain themselves, we’ve unlocked true hands-free, unattended operations—transforming operational efficiency and setting new standards for what truly autonomous cleaning can deliver to our customers.”

Experience at CMS Berlin

The Self-Cleaning Docking Station will debut at CMS Berlin 2025, held from September 23–26 at Messe Berlin, Germany. Visitors can discover the innovation at Hall 2.2, Stand 218.

About PUDU

Pudu Robotics, a global leader in the service robotics sector, is dedicated to enhancing human productivity and living standards through innovative robot technology. Pudu Robotics has taken the lead in establishing a comprehensive range of specialized, semi-humanoid, and humanoid robotic products in the industry. Currently, Pudu Robotics offers three product lines: service delivery robots, commercial cleaning robots, and industrial delivery robots, which are deployed across ten major industries, including food and beverage, retail, hospitality, healthcare, entertainment and sports, industrial facilities, education, and more. To date, Pudu Robotics has successfully shipped over 100,000 units to a variety of markets, with a presence in more than 1,000 cities across 80+ countries and regions worldwide.  For more information on business developments and updates, follow PUDU on LinkedIn, Facebook, YouTube, Twitter and Instagram.

Tencent Music Entertainment Group Announces New Audit Committee Member

SHENZHEN, China, Sept. 23, 2025 /PRNewswire/ — Tencent Music Entertainment Group (“TME”, or the “Company”) (NYSE: TME and HKEX: 1698), the leading online music and audio entertainment platform in China, today announced that its Board of Directors (the “Board”) approved the appointment of Ms. Jeanette Kim Yum Chan, an independent director of the Board, as a member of the audit committee, effective September 23, 2025.

Ms. Chan has served as a member of our Board, and, for purposes of the Hong Kong Listing Rules, an independent non-executive director, since September 2022. Ms. Chan has been working in Airwallex (Cayman) Limited (“Airwallex”), a global cross-border payments company, since 2019, and is currently the chief legal, compliance and risk officer of the group of Airwallex. Prior to Airwallex, she served as the managing partner of the China practice at Paul, Weiss, Rifkind, Wharton & Garrison LLP, an international law firm where her practice focused on cross-border mergers and acquisitions and private equity investments, with an emphasis on joint venture transactions and in the telecommunications, IT and media markets in the Asia Pacific region from 1986 to 2019. Ms. Chan is qualified to practice law in New York, British Columbia (Canada) and Hong Kong and is a non-practising solicitor of England and Wales. She obtained a Bachelor of Arts from the University of Toronto in Canada in 1980, a Bachelor of Laws from the University of British Columbia in Canada in May 1983, and a Master’s degree in Law from Harvard University in the United States in June 1986.

About Tencent Music Entertainment

Tencent Music Entertainment Group (NYSE: TME and HKEX: 1698) is the leading online music and audio entertainment platform in China, operating the country’s highly popular and innovative music apps: QQ Music, Kugou Music, Kuwo Music and WeSing. TME’s mission is to create endless possibilities with music and technology. TME’s platform comprises online music, online audio, online karaoke, music-centric live streaming and online concert services, enabling music fans to discover, listen, sing, watch, perform and socialize around music. For more information, please visit ir.tencentmusic.com.

Investor Relations Contact
Tencent Music Entertainment Group
ir@tencentmusic.com  
+86 (755) 8601-3388 ext. 885034

VCT 2025: China Stage 2 Playoffs Conclude in Triumph

CHONGQING, China, Sept. 23, 2025 /PRNewswire/ — From August 20 to 24, the VCT 2025: China Stage 2, hosted by TJ Sports and organized by Hero Esports, successfully concluded at the Chongqing Science Hall.

The event drew over 20,000 VALORANT fans to the venue. The stage boasted a panoramic, wrap-around layout featuring a total of 12 massive screens, which provided a seamless 360-degree viewing experience. No matter where fans were seated, attendees could follow every critical moment of the matches in real time.

During the finals, the band Life Awaits electrified the crowd with a powerful performance of the VCT CN theme song You Call Me Reckless. Amid roaring cheers, Bilibili Gaming (BLG) and Dragon Ranger Gaming (DRG) took the stage to battle for the championship.

BLG defeated DRG with a decisive 3-1 score, claiming the 2025 VCT CN annual championship and securing their first-ever league title. Player BLG.whzy was awarded the FMVP.

Cross-Community Fun: VALORANT 2nd Anniversary Carnival Turns Up the Heat

Beyond the matches at the Science Hall, the VALORANT 2nd Anniversary Carnival offered a diverse array of exciting activities. From music parties and community challenges to a stunning drone light show, VALORANT fans joined together to set Chongqing ablaze with energy.

The carnival brought together streamers, pro players, and cross-industry influencers, blending esports with basketball, rap, street dance, and other trendy elements to create a fully immersive experience. Surprise appearances by famous Chinese rappers Lan Lao and GALI, as well as comedian Fu Hang, added to the excitement. Basketball star Guo Ailun also made a special appearance at the “Aim Training Camp.”

An exclusive EDM party for VALORANT fans kicked into high gear. Six renowned DJs, including ISOxo and RL Grime, gathered in Chongqing, delivering explosive beats that defined the ultimate live experience. Meanwhile, on the evening of the 23rd, a breathtaking light show performed by 500 drones illuminated the night sky, showcasing VALORANT’s iconic elements.

According to statistics, the carnival attracted over 1.5 million offline attendees, while the global online and offline viewership reached over 100 million.

Onward to Paris: VCT CN Teams Ready for Champions

As the event drew to a close, rapper GAI took the stage, performing his hit song “Chaotianmen” to ignite the crowd and energize the CN teams preparing for their upcoming matches

BLG, DRG, EDG, and XLG were officially unveiled at the send-off ceremony. These four teams will head to Paris in September to represent the CN region at the VALORANT Champions 2025. With new battles on the horizon, they are ready to face the world’s best with courage and determination—giving their all in the pursuit of victory!

BLG claimed the 2025 VCT CN annual championship
BLG claimed the 2025 VCT CN annual championship

About Hero Esports

Founded in 2016, Hero Esports is the biggest esports company in Asia, producing more than 7,000 matches every year that captivate an online fan base of over 800 million. Headquartered in Shanghai and employing more than 1,100 employees, Hero Esports boasts a global presence encompassing 12 office locations and eight top-tier esports arenas. Hero Esports offers a comprehensive suite of esports services, including tournament organization, marketing solutions, community development, and more.

Orbit Flex Brings Hedge Fund-Level Investment Research and AI to All Investors

New model democratizes access to financial research, widening use of exclusive financial data and workflows on Orbit Insight

LONDON, Sept. 23, 2025 /PRNewswire/ — Orbit Financial Technology today announced a new monthly membership system for Orbit Insight, its flagship research and analysis platform already used by leading asset managers and hedge funds. The change opens access to smaller firms, boutique funds, and independent researchers, giving them the same institutional-grade tools trusted by global investment houses.

 

Orbit Insight combines Orbit’s exclusive financial data with advanced AI infrastructure, including Retrieval-Augmented Generation (RAG) technology, to help investors screen tens of thousands of companies at once and conduct reliable multi-document analysis. The new membership model, called Orbit Flex, increases access to this capability, removing cost and access barriers and allowing a much broader audience to harness AI-driven insights.

Both research teams and individual investors have traditionally faced limits on the volume of data they can process, forcing painful choices around coverage. Orbit’s AI infrastructure enables users to screen tens of thousands of companies simultaneously, powered by Retrieval-Augmented Generation (RAG) technology for reliable multi-document analysis. In addition to Orbit’s exclusive data and analytics, users can import their own data into the Orbit environment.

Orbit integrates into leading large language models, including Claude, Copilot and ChatGPT.

Da Wei, Founder and CEO of Orbit Financial Technology, said: “The true magic of large language models is in unlocking previously impossible workflows. With the right data and our infrastructure, specialist institutional and sophisticated retail investors can tackle any research challenge without custom training. Democratizing access has also been a core tenet of Orbit. That’s why I’m thrilled that, after a decade of development, we can now make this advanced capability accessible to everyone”.

Unlike traditional data vendors charging blanket licensing fees, Orbit’s transparent credit-based system ensures users pay only for what they use. The platform also includes an “Agent marketplace”, allowing users to deploy AI agents tailored to their investment strategies. Popular agents include Filings Insight Extractor, Portfolio News Tracker and Data Transformer, as well as sustainability agents such as an Anti-greenwashing monitor.

Orbit has built one of the market’s most comprehensive financial data infrastructures. The platform processes over 70 million documents annually across 150,000+ companies in 80 countries, delivering unmatched market intelligence and regulatory insights. Get started with a complementary trial at orbitfin.ai/flex.

About Orbit

Orbit is a sophisticated AI-powered financial services platform designed to empower informed, data-driven decision-making. Founded in 2015, Orbit processes over 70 million documents annually across 150,000+ companies in 80 countries, delivering unmatched market intelligence and regulatory insights. Our platform combines comprehensive data coverage with advanced AI capabilities to transform unstructured data into actionable intelligence for asset managers, hedge funds, data vendors, exchanges, and software platforms. For more information, visit orbitfin.ai.

Autumn Strolls in Weihai: Romance with Mountains and Sea

BEIJING, Sept. 23, 2025 /PRNewswire/ — A news report from CRI Online

With the crisp autumn breeze, it’s the perfect season for travel. Scenic spots across Weihai are now bathed in a unique autumn charm, drawing countless visitors eager to soak in the beauty of the mountains and sea.

At Banyue Wan in Huancui District, the pristine sandy beach and crystal-clear waters create a stunning contrast. Newly added swings and other attractions have quickly become must-visit photo spots. As the autumn wind gently brushes by, visitors wander barefoot along the shore, splash in the waves, or speed across the sea on jet skis—feeling the thrill and freedom of the ocean.

This autumn, step into Weihai. Let the embrace of mountains and sea soothe your soul, slow down, soak in every breathtaking view, and carry home memories long after the season fades.

 

Zoomlion Extends “Love Changes Destiny” Program into 23rd Year, Driving Global Community Development

Company donates over US$ 280,000 in 2025, with total contributions surpassing US$5.3 million

CHANGSHA, China, Sept. 23, 2025 /PRNewswire/ — Following the recent International Day of Charity, Zoomlion Heavy Industry Science & Technology Co., Ltd. (“Zoomlion”; 1157.HK) reaffirmed its long-standing commitment to social responsibility by donating RMB 2 million (approx. US$ 280,000) to this year’s “Love Changes Destiny” scholarship initiative.

Since its launch in 2003, the program has continued for 23 consecutive years, with cumulative donations now exceeding RMB 38 million (approx. US$5.3 million), providing vital support for hundreds of thousands of students to pursue their education. This enduring effort highlights Zoomlion’s responsibility in its home market while also reflecting the company’s broader commitment to community development across the globe.

The 2025 “Love Changes Destiny” ceremony was held in Changsha, bringing together government, charity, and business representatives to support students in need. Attendees heard stories from beneficiaries who shared how the program inspired them to persevere and contribute back to society. Zoomlion also contributed an additional RMB 800,000 through the Hunan Charity Federation to assist students from ethnic minority backgrounds in rural regions, reinforcing its focus on inclusive development.

Over more than two decades, the program has raised billions of yuan and helped support nearly 255,000 students, with Zoomlion recognized as a key contributor and recipient of major national charity awards.

Zoomlion’s dedication to social responsibility extends well beyond China’s borders. In Vietnam, the company supported post-disaster recovery in Bac Ha County following Typhoon Yagi in 2024 by donating essential supplies and helping rebuild infrastructure for highland villages. In the Philippines, its local subsidiary recently organized a charity event at the Rehoboth Sampaloc orphanage in Rizal Province, delivering food, baby care items, and toys for 27 children. The company has also participated in agricultural cooperation projects in countries such as Cambodia, Laos, and the Dominican Republic, providing equipment and training to support modernization and sustainable development.

Zoomlion combines local action with global responsibility, linking its growth as a leading equipment manufacturer with long-term contributions to education, disaster relief, and agricultural advancement. As the company expands its global footprint, it remains committed to initiatives that foster community resilience and sustainable development, demonstrating that corporate responsibility and global citizenship are central to its long-term vision.

 

Kelun-Biotech to Present Results from Multiple Clinical Studies at the 2025 ESMO Congress

CHENGDU, China, Sept. 23, 2025 /PRNewswire/ — The 2025 European Society for Medical Oncology (ESMO) Congress will take place in Berlin, Germany, from October 17 to 21. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun-Biotech”, HKEX: 6990) will present results from multiple clinical studies at the congress, including data from its TROP2 ADC sacituzumab tirumotecan (sac-TMT), HER2 ADC A166 (trastuzumab botidotin), and CLDN18.2 ADC SKB315. Among these, two Phase III clinical studies of sac-TMT were selected for the Latest Breakthrough Abstracts (LBA) and presented as oral reports, including one featured in the Presidential Symposium; one Phase III clinical study of A166 was selected for LBA and presented as oral report.

Abstract titles of these studies have been published on the official website of ESMO. The study results to be presented include:

Title: Sacituzumab tirumotecan (sac-TMT) vs platinum-based chemotherapy in EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC) following progression on EGFR-TKIs: results from the randomized, multi-center phase 3 OptiTROP-Lung04 study
Presentation Type: Presidential Symposium 
Presentation #: LBA5
Date and Lecture Time: October 19, 4:52 PM to 5:04 PM local time

Title: Sacituzumab tirumotecan (sac-TMT) vs investigator’s choice of chemotherapy (ICC) in previously treated locally advanced or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): results from the randomized, multi-center phase 3 OptiTROP-Breast02 study
Presentation Type: Proffered Paper
presentation #: LBA23
Date and Lecture Time: October 18, 10:45 AM to 10:55 AM local time

Title: Trastuzumab botidotin vs trastuzumab emtansine (T-DM1) in HER2-positive unresectable or metastatic breast cancer: results from a randomized phase 3 study
Presentation Type: Proffered Paper 
presentation #: LBA24
Date and Lecture Time: October 18, 10:55 AM to 11:05AM local time

Title: SKB315, a novel Claudin 18.2 (CLDN18.2) antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors including gastric/ gastroesophageal junction cancer (GC/GEJC): a phase 1 study
Presentation Type: Poster
Presentation #: 2139P
Date and Session Time: October 19, 9:00 AM to 5:00 PM local time

Title: Sacituzumab tirumotecan (sac-TMT) in Participants (pts) with Previously Treated, Advanced KRAS-Mutant NSCLC: Results from Cohort 5d of the SKB264-II-08 Study
Presentation Type: Poster
Presentation #: 1945P
Date and Session Time: October 18, 9:00 AM to 5:00 PM local time

Title: Sacituzumab tirumotecan (sac-TMT) + pembrolizumab[1] (pembro) for treatment-naïve advanced PD-L1 positive NSCLC: results from the Phase 2 MK-2870-003/SKB264-II-04 study
Presentation Type: Poster
Presentation #: 1949P
Date and Session Time: October 18, 9:00 AM to 5:00 PM local time

Title: Sacituzumab tirumotecan (sac-TMT) + Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer (mCRPC): Results from Phase 2 MK-2870-002/SKB264-II-06 Study
Presentation Type: Poster
Presentation #: 2421P
Date and Session Time: October 18, 9:00 AM to 5:00 PM local time

Title: Sacituzumab tirumotecan (Sac-TMT) Monotherapy in Advanced/Metastatic Endometrial Carcinoma (EC): Results from a Phase 1/2 Study (MK-2870-001/KL264-01)
Presentation Type: Poster
Presentation #: 1111P
Date and Session Time: October 18, 9:00 AM to 5:00 PM local time

Title: Efficacy and Safety of sacituzumab tirumotecan (Sac-TMT) Monotherapy in Advanced/Metastatic Cervical Cancer: Results from a Phase 1/2 Study (MK-2870-001/KL264-01)
Presentation Type: Poster
Presentation #: 1168P
Date and Session Time: October 18, 9:00 AM to 5:00 PM local time

About sac-TMT 

Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, BC, gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells.

In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc., Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (includes Mainland China, Hong Kong, Macau, and Taiwan).

To date, 2 indications for sac-TMT have been approved and marketed in China for the treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting), EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy. In addition, two new indication applications for sac-TMT for the treatment of adult patients with EGFR-mutant locally advanced or metastatic NSCLC who progressed after treatment with EGFR-TKI therapy and with unresectable locally advanced, metastatic hormone receptor positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) BC who have received prior endocrine therapy and other systemic treatments in the advanced or metastatic setting were accepted by the Center for Drug Evaluation of NMPA, and were included in the priority review and approval process. As of today, the Company has initiated 9 registrational clinical studies in China. MSD has initiated 14 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab or other anti-cancer agents for several types of cancer. These studies are sponsored and led by MSD.

About Trastuzumab Botidotin (A166)

Trastuzumab botidotin is a differentiated HER2 ADC in new drug application (NDA) registration stage to treat advanced HER2+ solid tumors. As an innovative HER2 ADC developed by the Company, it conjugates a novel, MMAF derivative (a highly cytotoxic tubulin inhibitor, Duo-5) via a stable, enzyme-cleavable linker to a HER2 monoclonal antibody with a DAR of 2. Trastuzumab botidotin specifically binds to HER2 on the surface of tumor cells and is internalized by tumor cells, releasing the toxin molecule Duo-5 inside the cell. Duo-5 induces tumor cell cycle arrest in the G2/M phase, leading to tumor cell apoptosis. After targeting HER2, trastuzumab botidotin can also inhibit the HER2 signaling pathway; it has antibody-dependent cell-mediated cytotoxicity (ADCC) activity.

Based on the results of a randomized, controlled, open-label Phase III study, the New Drug Application (NDA) for trastuzumab botidotin was accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in January 2025 for the treatment of adult patients with HER2+ unresectable or metastatic BC who have received at least one prior anti-HER2 therapy was accepted by the CDE of the NMPA. At a pre-specified interim analysis, trastuzumab botidotin monotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS) as assessed by the Blinded Independent Central Review (BICR) compared with T-DM1.

Currently, Kelun-Biotech has initiated an open, multi-center Phase II clinical study of trastuzumab botidotin in the treatment of HER2+ unresectable or metastatic BC that previously received a topoisomerase inhibitor ADC.

About SKB315

SKB315 is a novel CLDN18.2 ADC targeting advanced solid tumors configured with a proprietary, in-house developed humanized CLDN18.2 mAb and a differentiated payload-linker design. Currently, Kelun-Biotech has initiated the exploration in combination with immunotherapy for gastric/gastroesophageal junction cancer (GC/GEJC) while advancing monotherapy studies for tumors expressing CLDN18.2, such as GC/GEJC and pancreatic cancer.

About Kelun-Biotech

Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical (002422.SZ), which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 2 projects are in the NDA stage and more than 10 projects are in the clinical stage. The company has established one of the world’s leading proprietary ADC and novel DC platforms, OptiDC™, and has 1 ADC project approved for marketing,1 ADC project in NDA stage and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://kelun-biotech.com/.

[1] Pembrolizumab (KEYTRUDA®) is a registered trademark of Merck Sharp & Dohme LLC (MSD), a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.